On October 2, 2026 MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, reported two poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first presentation examines agenT-797 alone and in combination with botensilimab and balstilimab (BOT+BAL) in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases. This preclinical research supports the rationale for the ongoing Phase 2 trial at Scripps, led by Darren Sigal, M.D., evaluating the combination in patients with previously treated microsatellite-stable (MSS) metastatic colorectal cancer with liver metastases (NCT07550088).
The second examines native agenT-797 and engineered MiNK-215, a FAP-targeting CAR-iNKT cell therapy incorporating IL-15, in oncogenic in vitro models of senescent tumor cells and fibroblasts.
Together, the presentations highlight complementary opportunities for MiNK’s platform; addressing treatment-resistant cancer and targeting senescent cancer and stromal cells.
Poster Presentation Details
Title: Native and engineered allogenic invariant natural killer T (iNKT) cells eliminate senescent tumor cells and fibroblasts in oncogenic in vitro models
Presenter: Jing Fang, Ph.D., Postdoctoral Fellow in the laboratory of Jesús Gil, MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
Date: Friday, November 6, 2026
Times: 12:15–1:45 p.m.; 6:40–8:10 p.m. MST
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4–6
Poster No.: 177
Title: agenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
Presenter: Shanmugarajan Krishnan, Ph.D., M.S., B.S.; Agenus Inc., Lexington, MA
Date: Saturday, November 7, 2026
Times: 12:15–1:45 p.m.; 6:40–8:10 p.m. MST
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4–6
Poster No.: 270
(Press release, MiNK Therapeutics, OCT 2, 2026, https://www.globenewswire.com/news-release/2026/10/02/3373825/0/en/mink-therapeutics-to-present-data-on-treatment-resistant-colorectal-cancer-and-clearance-of-senescent-tumor-cells-and-fibroblasts-at-sitc-2026.html [SID1234671255])